Crossmark

Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report

Crossref DOI link: https://doi.org/10.1186/s13256-020-02363-3

Published Online: 2020-03-17

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Liu, Yao-Chung

Lin, Ting-An

Wang, Hao-Yuan

Ko, Po-Shen

Liu, Chia-Jen

Hsiao, Liang-Tsai

Chien, Sheng-Hsuan

Gau, Jyh-Pyng
Funding

Funding for this research was provided by:

Mundipharma (China) Pharmaceutical
License Information

Text and Data Mining valid from 2020-03-17

Version of Record valid from 2020-03-17
More Information

Article History

Received: 24 October 2019

Accepted: 20 February 2020

First Online: 17 March 2020

Ethics approval and consent to participate

: Written informed consent for publication of this paper was obtained from the patient.

: Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below